UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival

European journal of nuclear medicine and molecular imaging, 2018, Vol.45 (1), p.12-19

2018

Volltextzugriff (PDF)

Immunonkologische Therapie des Harnblasenkarzinoms – quo vadis? Update zu aktuellen Studien und weiteren Entwicklungen

Urologe. Ausgabe A, 2020-07, Vol.59 (7), p.810-816

2020

Volltextzugriff (PDF)

Genitourinary malignancies and rheumatoid arthritis

Zeitschrift für Rheumatologie, 2016-02, Vol.75 (1), p.54-62

2016

Volltextzugriff (PDF)

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

European urology open science (Online), 2020-07, Vol.19, p.e871-e872

2020

Volltextzugriff (PDF)

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The lancet oncology, 2015-02, Vol.16 (2), p.152-160

2015

Volltextzugriff (PDF)

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

The New England journal of medicine, 2013-01, Vol.368 (2), p.138-148

2013

Volltextzugriff (PDF)

1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS

Annals of oncology, 2023-10, Vol.34, p.S964-S964

2023

Volltextzugriff (PDF)

Was gab es Neues auf den Kongressen 2015? – Update Uroonkologie

Aktuelle Urologie, 2016-02, Vol.47 (1), p.27-35

2016

Volltextzugriff (PDF)

177Lu-PSMA-Therapie: Aktuelle Evidenzlage beim Einsatz in der Behandlung von Patienten mit metastasiertem Prostatakarzinom

Urologe. Ausgabe A, 2017-11, Vol.56 (11), p.1440-1444

2017

Volltextzugriff (PDF)

Urologische Malignome und rheumatoide Arthritis

Zeitschrift für Rheumatologie, 2016-02, Vol.75 (1), p.54-62

2016

Volltextzugriff (PDF)

Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma

The Journal of urology, 2017-12, Vol.198 (6), p.1253-1262

2017

Volltextzugriff (PDF)

2378P Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment

Annals of oncology, 2023-10, Vol.34, p.S1211-S1211

2023

Volltextzugriff (PDF)

Was gab es Neues auf den Kongressen 2014? – Update Uroonkologie

Aktuelle Urologie, 2015-03, Vol.46 (2), p.106-117

2015

Volltextzugriff (PDF)

LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)

Annals of oncology, 2024-09, Vol.35, p.S1271-S1272

2024

Volltextzugriff (PDF)

LBA85 TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)

Annals of oncology, 2024-09, Vol.35, p.S1272-S1273

2024

Volltextzugriff (PDF)

1980P Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial

Annals of oncology, 2024-09, Vol.35, p.S1145-S1146

2024

Volltextzugriff (PDF)

955PEffect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Effect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry

Annals of oncology, 2019-10, Vol.30, p.v386

2019

Volltextzugriff (PDF)

955P - Effect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry

Annals of oncology, 2019-10, Vol.30, p.v386-v386

2019

Volltextzugriff (PDF)

1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial

Annals of oncology, 2023-10, Vol.34, p.S978-S979

2023

Volltextzugriff (PDF)

1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial

Annals of oncology, 2022-09, Vol.33, p.S1164-S1165

2022

Volltextzugriff (PDF)

620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update

Annals of oncology, 2020-09, Vol.31, p.S512-S513

2020

Volltextzugriff (PDF)

P128 ArtemisR: Final analysis of a European real-world retrospective study of mHSPC patients treated with apalutamide

European urology open science (Online), 2024-11, Vol.69, p.162-163

2024

Volltextzugriff (PDF)

P262 TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy: interim analysis of SunRISe-4

European urology open science (Online), 2024-11, Vol.69, p.332-333

2024

Volltextzugriff (PDF)

Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape

Annals of oncology, 2017-09, Vol.28, p.v318-v319

2017

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(86)

Publikationsform

Sprache

Deutsch
(72)
Englisch
(42)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Medicine
(19)
Medicine & Public Health
(19)
Humans
(16)
Urology
(15)
Male
(13)
Prostate Cancer
(11)
Biological And Medical Sciences
(10)
Urology & Nephrology
(10)
Fundamental And Applied Biological Sciences. Psychology
(9)
Plant Sciences
(9)
Oncology
(8)
Plants
(8)
Treatment Outcome
(8)
Plant Roots
(7)
Animal And Plant Ecology
(6)
Animal, Plant And Microbial Ecology
(6)
Chemotherapy
(6)
Nephrology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival

Immunonkologische Therapie des Harnblasenkarzinoms – quo vadis? Update zu aktuellen Studien und weiteren Entwicklungen

Genitourinary malignancies and rheumatoid arthritis

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS

Was gab es Neues auf den Kongressen 2015? – Update Uroonkologie

177Lu-PSMA-Therapie: Aktuelle Evidenzlage beim Einsatz in der Behandlung von Patienten mit metastasiertem Prostatakarzinom

Urologische Malignome und rheumatoide Arthritis

Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma

2378P Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment

Was gab es Neues auf den Kongressen 2014? – Update Uroonkologie

LBA84 TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)

LBA85 TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)

1980P Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial

955PEffect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry

Effect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry

955P - Effect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry

1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial

1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial

620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update

P128 ArtemisR: Final analysis of a European real-world retrospective study of mHSPC patients treated with apalutamide

P262 TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy: interim analysis of SunRISe-4

Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape

Suchergebnisse filtern